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novel targeted treatment approaches on the outcome of pts will be subject 
of future analyses.
Disclosure Statement: None of the authors has declared a conflict of interest 
regarding the subject of this work. 
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Patients with Metastatic Non-Small Cell Lung Cancer without 
Molecular Alterations or PD-L1 Expression in Germany. 
Treatment and First Outcome from The Prospective German 
Registry Platform Crisp (AIO-TRK-0315)
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Purpose: Guidelines for stage IV NSCLC recommend stratified treatment 
by biomarker test results. We used CRISP to evaluate treatment and out-
come of patients (pts) in whom neither targetable molecular alterations 
nor any PD-L1 expression were detected.
Methods: Currently 163 sites in Germany have recruited >4255 pts at start 
of 1st-line who will be followed until death or end of project. Data from 
2204 pts recruited by 133 sites from 12/2015 to 06/2018 was analyzed. 
These pts started treatment prior approval of immune checkpoint inhibi-
tors (ICI) for this group of pts. Progression-free survival (PFS) was deter-
mined in pts ≥1 year under observation (recruited until 06/2017 (n=906), 
outcome sample (ous)).
Results: 6% of pts with non-squamous (nsq) and 35% with squamous (sq) 
tumors received no type of biomarker testing prior to start of 1st-line, and 
in 49% and 36% no targetable alterations or any PD-L1 expression were 
detected. Thus, 55% and 71% of pts (nsq/sq) were eligible for chemother-
apy (ctx) but no type of targeted therapy at start of 1st-line. 
In 1st-line, pts received carboplatin- (55%) or cisplatin-based ctx (24%), 
13% targeted therapy (e.g. ICI in trial, switch to TKI but test result not yet 
documented).
At database cut, 33% of all pts had started 2nd-line, 24% had died prior to a 
2nd-line and remaining pts were still in 1st-line. In the ous, median PFS was 
5.0 months (66% events, 95%-CI 4.5-5.5 months, n=457) for nsq tumors 
and 4.5 months (66% events, 95%-CI 3.4-5.3 months, n=154) for sq tu-
mors. In total 55% of pts with nsq and 53% of pts with sq tumors had died.
Conclusions: Despite break-throughs with targeted therapies and high 
test rates in routine care, the majority of pts do not qualify for targeted 
therapy. First outcome results indicate that prognosis is poor in these pts. 
Outcome will hopefully improve in the cohort now treated with ctx-ICI 
combination.
Disclosure Statement: None of the authors has declared a conflict of interest 
regarding the subject of this work. 
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Purpose: Immune checkpoint blockade targeting the PD-1/PD-L1 pathway 
in combination with platinum-based chemotherapy (CT) has demonstrated 
improved clinical outcomes in patients (pts) with extensive-stage small-cell 
lung cancer (ES-SCLC). Treatment with durvalumab (D), a selective, high-af-
finity, human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, and 
tremelimumab (T), a selective human IgG2 mAb against CTLA-4, may pro-
vide possible additive or synergistic effects. Durvalumab demonstrated dura-
ble clinical activity and had a manageable safety profile both as monothera-
py and in combination with tremelimumab in pts with pretreated ES-SCLC 
(NCT01693562; NCT02261220; NCT02937818). CASPIAN (NCT03043872) 
is a randomised, multicentre, open-label, sponsor-blind, Phase 3 study of 
Durvalumab ± Tremelimumab in combination with etoposide and plati-
num-based CT (EP) as first-line treatment for pts with ES-SCLC.
Methods: In total, 804 pts were randomised 1:1:1 to receive D 1500 mg + 
T 75 mg + EP q3w for 4 cycles, followed by D 1500 mg q4w until disease 
progression (PD), with one additional dose of T given post EP (Arm 1); D 
1500 mg + EP q3w for 4 cycles, followed by D 1500 mg q4w until PD (Arm 
2); or EP q3w for 4–6 cycles with prophylactic cranial irradiation if indicat-
ed (Arm 3). Randomisation was stratified by platinum-based CT in cycle 1 
(carboplatin vs cisplatin). Pts had histologically or cytologically document-
ed ES-SCLC, WHO/ECOG PS 0 or 1 and were suitable to receive first-line 
platinum-based CT. The primary endpoint was overall survival (OS) for D 
± T + EP versus EP. Secondary endpoints included progression-free sur-
vival (PFS); objective response rate; landmark OS and PFS rates; safety and 
tolerability; pharmacokinetics; immunogenicity; quality of life.
Results: Results will be presented at WCLC 2019 including OS, key sec-
ondary endpoints, safety and tolerability.
Conclusions: Not applicable.
Reference: 
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